Status:
UNKNOWN
Comparative Study of EDP-420 Versus Another Antibiotic in the Treatment of Community Acquired Pneumonia
Lead Sponsor:
Enanta Pharmaceuticals, Inc
Conditions:
Community Acquired Pneumonia
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This study will compare the efficacy, safety and tolerability of EDP-420 versus another oral antibiotic in the treatment of community acquired pneumonia
Eligibility Criteria
Inclusion
- Recent respiratory illness with signs and symptoms and chest X-ray consistent with the diagnosis of community-acquired pneumonia.
- Suitable candidate for oral antibiotic therapy and able to swallow large capsules intact
- If female, must be non-lactating and at no risk for pregnancy
Exclusion
- Other infections
- Other pulmonary diseases requirement multiple antibacterial medications or long duration of therapy
- History of hypersensitivity, allergic or adverse reactions to macrolide, ketolide, azalide or streptogramins
- Evidence of uncontrolled clinically significant disease, malignancy, or other abnormality
- Requirement of parenteral antimicrobial therapy for treatment of pneumonia
- Currently receiving or likely to receive any known inhibitors or inducers of cytochrome P450 mediated drug metabolism
- Immunocompromised subjects
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
End Date :
July 1 2007
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT00270517
Start Date
December 1 2005
End Date
July 1 2007
Last Update
September 19 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Enanta Pharmaceuticals, Inc.
Watertown, Massachusetts, United States, 02472